RT Journal Article SR Electronic T1 â–¼Atovaquone + proguanil for malaria prophylaxis JF Drug and Therapeutics Bulletin JO Drug Ther Bull FD BMJ Publishing Group Ltd SP 73 OP 75 DO 10.1136/dtb.2001.391073 VO 39 IS 10 YR 2001 UL http://dtb.bmj.com/content/39/10/73.abstract AB Relevant BNF section: 5.4.1&#9660Atovaquone + proguanil* (Malarone - GlaxoSmithKline) is a fixed-dose combination of two antiparasitic drugs. In 1996, it was licensed in the UK for the treatment of acute, uncomplicated falciparum malaria. Earlier this year, the combination was licensed additionally for prophylaxis of falciparum malaria. The manufacturer claims that, when used for prophylaxis, atovaquone + proguanil "offers 97% efficacy with a side effect profile similar to placebo". Here, we assess these claims and review the place of atovaquone + proguanil as prophylaxis for non-immune people travelling from the UK.